GSK beat six other companies to the Sierra deal table and prevailed after initial $46 per share bid

Kyle LaHucik

Senior Reporter

Within weeks of Sierra Oncology revealing it had taken a failed Gilead JAK inhibitor and turned it into a Phase III success, GlaxoSmithKline swooped in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK beat six other companies to the Sierra deal table and prevailed after initial $46 per share bid

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

GSK beat six oth­er com­pa­nies to the Sier­ra deal ta­ble and pre­vailed af­ter ini­tial $46 per share bid

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

GSK beat six other companies to the Sierra deal table and prevailed after initial $46 per share bid